Assessment of clinical characteristics and treatment outcomes of pediatric patients with intracardiac thrombosis: a single-center experience

被引:1
作者
Al, Isik Odaman [1 ]
Oymak, Yesim [1 ]
Erdem, Melek [1 ]
Tahta, Neryal [1 ]
Acar, Sultan Okur [1 ]
Mese, Timur [2 ]
Yilmazer, Murat Muhtar [2 ]
Gozmen, Salih [1 ]
Zihni, Cuneyt [2 ]
Calkavur, Sebnem [3 ]
Karapinar, Tuba Hilkay [1 ]
机构
[1] Dr Behcet Uz Traning & Res Hosp, Dept Pediat Hematol & Oncol, Izmir, Turkey
[2] Dr Behcet Uz Traning & Res Hosp, Dept Pediat Cardiyol, Izmir, Turkey
[3] Dr Behet Uz Traning & Res Hosp, Dept Neonatol, Izmir, Turkey
关键词
cardiomyopathy; catheter-related thrombosis; childhood thrombophilia; children; congenital heart disease; intracardiac thrombosis; thrombus; TISSUE-PLASMINOGEN ACTIVATOR; RANDOMIZED CONTROLLED-TRIAL; VENOUS THROMBOEMBOLISM; CARDIAC PATHOLOGY; CHILDREN; RISK; MANAGEMENT; CHILDHOOD; COMPLICATIONS; PREVENTION;
D O I
10.1097/MBC.0000000000001100
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The prevalence of intracardiac thrombus (ICT) is gradually increasing, though it is rare among children. Data related to the occurrence of ICT among children are limited, and treatment recommendations have been made utilizing adult guidelines. The primary objective of this study is to determine associated factors, management, and outcomes of intracardiac thrombosis in children. Between January 2013 and January 2020, patients diagnosed with ICT at the Pediatric Hematology-Oncology and Pediatric Cardiology departments in our hospital were included in the study. Demographic characteristics, clinical and laboratory findings, treatment protocols, and outcomes were analyzed retrospectively. The median age at diagnosis was 10.5 months (2 days to 14.5 years), and the median followup period was 6.5 months (1 month to 3.1 years). The most common primary diagnoses of the patients, in order of frequency, were heart disease (n: 8), metabolic disease (n: 3), prematurity and RDS (n: 3), burns (n: 2), pneumonia (n: 2), and asphyxia (n: 2). CVC was present in 19/23 of the patients. The reasons for CVC insertion were the need for plasmapheresis in one patient with a diagnosis of HUS and the need for well tolerated vascular access because of longterm hospitalization in others. LMWH was administered to all patients as first-line therapy. Complete response was achieved in 19 (79%) of 24 patients and 4 patients (16.6%) were unresponsive to medical treatment. It was found out that the thrombus location, type, sepsis, and hemoculture positivity, as well as the presence of CVC, had no impact on treatment response (chi-square PU0.16, 0.12, 0.3, 0.49, 0.56). Moreover, no correlation was determined between thrombus size and treatment response (Mann Whitney U test PU0.47). The mortality rate was determined to be 12.5% (3/24). Spontaneous occurrence of ICT is rare in childhood, without any underlying primary disease or associated factor. The presence of CVC, sepsis, and heart disease are factors associated with ICT. The success rate is increased with medical treatment. There was no significant difference in treatment response between the newborn and 1 month to 18-year-old patient group. It has been demonstrated that thrombus size, type, localization; sepsis, and hemoculture positivity had no impact on the treatment response. Blood Coagul Fibrinolysis 33:34- 41 Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:34 / 41
页数:8
相关论文
共 39 条
  • [1] Thrombosis in children with cardiac pathology: analysis of acquired and inherited risk factors
    Alioglu, Bulent
    Avci, Zekai
    Tokel, Kursat
    Atac, F. Belgin
    Ozbek, Namik
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2008, 19 (04) : 294 - 304
  • [2] Allen Karen S, 2015, World J Crit Care Med, V4, P105, DOI 10.5492/wjccm.v4.i2.105
  • [3] Recombinant tissue plasminogen activator for the management of intracardiac thrombi in newborns
    Alvarez Z, Patricia
    Verdugo L, Patricia
    Carvajal K, Luis
    Muhlhausen M, German
    Rios A, Patricia
    Rodriguez, Diego, V
    [J]. REVISTA CHILENA DE PEDIATRIA-CHILE, 2015, 86 (03): : 194 - 199
  • [4] Tissue Plasminogen Activator Use in Children: Bleeding Complications and Thrombus Resolution
    Ansah, Deidra A.
    Patel, Kavita N.
    Montegna, Leticia
    Nicholson, George T.
    Ehrlich, Alexandra C.
    Petit, Christopher J.
    [J]. JOURNAL OF PEDIATRICS, 2016, 171 : 67 - +
  • [5] Factor V 1691 G-A mutation in children with intracardiac thrombosis: a prospective study
    Atalay, S
    Akar, N
    Tutar, HE
    Yilmaz, E
    [J]. ACTA PAEDIATRICA, 2002, 91 (02) : 168 - 171
  • [6] Outcome of cardiac thrombi in infants
    Bendaly, Edgard A.
    Batra, Anjan S.
    Ebenroth, Eric S.
    Hurwitz, Roger A.
    [J]. PEDIATRIC CARDIOLOGY, 2008, 29 (01) : 95 - 101
  • [7] Thrombosis in children: Which test to whom, when and how much necessary?
    Celkan, Tiraje
    Dikme, Gurcan
    [J]. TURK PEDIATRI ARSIVI-TURKISH ARCHIVES OF PEDIATRICS, 2018, 53 (01): : 1 - 9
  • [8] Intracardiac Thrombus in Children: The Fine Equilibrium Between the Risk and the Benefit
    Cetin, Ibrahim Ilker
    Ekici, Filiz
    Unal, Sevim
    Kocabas, Abdullah
    Sahin, Sanliay
    Yazici, Mutlu Uysal
    Ayar, Ganime
    [J]. PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2014, 31 (05) : 481 - 487
  • [9] Thrombosis and embolism in pediatric cardiomyopathy
    Chen, Kai
    Williams, Suzan
    Chan, Anthony K. C.
    Mondal, Tapas K.
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2013, 24 (03) : 221 - 230
  • [10] A Single-Center Experience with Intracardiac Thrombosis in Children with Dilated Cardiomyopathy
    Choi, Soo-Han
    Jeong, Soo In
    Yang, Ji-Hyuk
    Kang, I-Seok
    Jun, Tae-Gook
    Lee, Heung-Jae
    Huh, June
    [J]. PEDIATRIC CARDIOLOGY, 2010, 31 (02) : 264 - 269